WALTHAM, Mass. & VIENNA--(BUSINESS WIRE)--Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, announced today that René Russo, PharmD, BCPS, chief executive officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference in Boston, MA.
The presentation will take place on Wednesday, March 8, 2017, at 10:00 a.m. EDT.
About Arsanis, Inc.
Arsanis is a clinical-stage
biotechnology company leading the development of targeted monoclonal
antibodies (mAbs) for pre-emptive therapy and treatment of serious
infectious diseases. The company’s current programs address pathogenic
processes selectively, aiming to preserve the healthy microbiome and
potentially allowing Arsanis to address critical infections without
contributing to the problem of resistance. The company is building a
broad product pipeline addressing the most important infectious diseases
that threaten patients globally. Its lead clinical program, ASN100, is
aimed at serious Staphylococcus aureus infections and is being
evaluated in a Phase 2 clinical study for the prevention of S. aureus
pneumonia in high-risk patients.
Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH). For more information, please visit the Arsanis website at www.arsanis.com.
